Adherence to aldosterone-blocking agents in patients with heart failure

American Journal of Therapeutics

Volumn 17, Issue 5, 2010, Pages 446-454

  Margolis, Jay ^a   Gerber, Robert A ^b   Roberts, Craig ^b   Gheorghiade, Mihai ^c  

^a Thomson Reuters   (United States)

^b PFIZER INC   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

adherence; aldosterone blockers; compliance; heart failure; persistence

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEALTH INSURANCE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE OVERLOAD; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL; UNSTABLE ANGINA PECTORIS;

AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77957763788     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181ea3213     Document Type: Article

References (22)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115: e69-e171.
2. American Heart Association. Heart disease and stroke statistics-2009 update. Dallas, TX: American Heart Association; 2009:20
3. Heart Failure Society of America. 2006 Comprehensive heart failure practice guideline. J Card Fail. 2006;12: e1-e122.
4. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-1140.
5. Ray JG, Gong Y, Sykora K, et al. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005;165:62-67.
6. Horwich TB, Mac Lellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43:642-648.
7. Komajda M, Follath F, Swedberg K, et al. The Euro Heart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe: part 2: treatment. Eur Heart J. 2003;24:464-474. (Pubitemid 36286188)
8. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, rando-mised, controlled clinical trial. Lancet. 2005;366:2005-2011.
9. Opasich C, Febo O, Riccardi PG, et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol. 1996;78:354-357.
10. Wang W. Chronic administration of aldosterone de-presses baroreceptor reflex function in the dog. Hyper-tension. 1994;24:571-575.
11. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
12. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery com-pliance in chronically treated heart failure patients. Eur Heart J. 1998;19:1371-1376.
13. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Eval-uation Study Investigators. N Engl J Med. 1999;341: 709-717.
14. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation. 2005;112: 39-47.
15. Witham MD, Gillespie ND, Struthers AD. Tolerability of spironolactone in patients with chronic heart failure: a cautionary message. Br J Clin Pharmacol. 2004;58:554-557.
16. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
17. Mc Murray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail. 2005;7:710-721.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
19. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-864.
20. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expen-ditures. Am J Manag Care. 2006;12:110-117.
21. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation. 2007;116:737-744.
22. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-convert-ing enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153-1158.